Veritas Pharma’s (VRT.C) new signing brings a 12% stock increase

Cannabis research play Veritas Pharmaceuticals (VRT.C) announced news after yesterday’s close, as predicted here at Equity.Guru, and the news was most definitely good.

If you’re in the cancer research field, you know the name of Dr. Donald Carlow. If you don’t, next time you’re in a cancer hospital, look up when you walk in and you’re likely to see the guy’s portrait hanging somewhere prominent.

He’s one of what the company has pegged as 3 independent directors, out of their 5 in total.

From the Veritas news release:

Dr. Donald R. Carlow is a Health Care Consultant, past CEO of the Canadian Association of Provincial Cancer Agencies (CAPCA) past President and CEO of the Ontario Cancer Institute/Princess, Margaret Hospital and the past President and CEO of the British Columbia Cancer Agency. He was a member of the governing council of the Canadian Strategy for Cancer Control, has consulted widely on provincial Cancer control systems throughout Canada and was recently a member of the board of the Vancouver Island Health Authority.


I’m going to just leave that here, point to today’s 12% stock price jump, and back slowly out of the room.

–Chris Parry

FULL DISCLOSURE: I’m a consultant for Veritas, and increasingly proud of it.

Disclaimer: ALWAYS DO YOUR OWN RESEARCH and consult with a licensed investment professional before making an investment. This communication should not be used as a basis for making any investment.

Leave a Reply

Be the First to Comment!

Notify of